Boston Scientific received FDA 510(k) clearance for its SpyGlass DS Direct Visualization System.
The system is cleared for use in the diagnosis and treatment of pancreatico-biliary disease. The first cases involving use of the system were cholangioscopy and pancreatoscopy procedures. The system is built on the technology of the original SpyGlass System, and aims to optimize procedural efficiency and productivity.
More articles on GI/endoscopy:
GI physician leader to know: Dr. Anthony DiMarino of Jefferson University Hospitals
Boston Scientific SVP sold 11k+ shares: 4 things to know
APIC, SHEA address infections linked to duodenscopes